Irina Bancos, MD
Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1659552412
Payments from drug & device makers
Across 270 payments — averaging $17,933 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esteve Pharmaceuticals LLC$3.7M
- Ascendis Pharma Endocrinology Inc$730K
- Neurocrine Biosciences, Inc.$227K
- Corcept Therapeutics$123K
- Recordati_rare_diseases_inc.$53K
- AstraZeneca$16K
- plus $27K from 6 others
Across 142 payments — averaging $2947.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$292K
- Recordati_rare_diseases_inc.$126K
- Corcept Therapeutics$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esteve Pharmaceuticals LLC | 13 | $3,664,444 |
| Ascendis Pharma Endocrinology Inc | 24 | $730,402 |
| Neurocrine Biosciences, Inc. | 74 | $226,909 |
| Corcept Therapeutics | 34 | $123,375 |
| Recordati_rare_diseases_inc. | 95 | $53,305 |
| AstraZeneca | 15 | $16,040 |
| Novo Nordisk | 5 | $11,074 |
| HRA Pharma RARE Diseases | 4 | $10,369 |
| Progenics Pharmaceuticals, Inc. | 2 | $2,186 |
| Strongbridge US Inc. | 1 | $1,800 |
| Astrazeneca UK Limited | 1 | $1,611 |
| Xeris Pharmaceuticals, Inc. | 2 | $394 |
How this compares
$4,841,908 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Rochester
- Yogish KudvaRochester$2.9M
- Marius StanRochester$2.2M
- John MorrisRochester$1.9M
- Adrian VellaRochester$1.7M
- Mabel RyderRochester$691K
- Manpreet MundiRochester$388K
- Bart ClarkeRochester$298K
- Marjorie Ann MalbasRochester$222K
- Robert WermersRochester$188K
- Diane DoneganRochester$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.